<DOC>
	<DOCNO>NCT01006590</DOCNO>
	<brief_summary>The study evaluate efficacy tolerability saxagliptin compare uptitration metformin patient type 2 diabetes inadequate glycaemic control submaximal dose metformin .</brief_summary>
	<brief_title>Efficacy Tolerability Saxagliptin add-on Compared Uptitration Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Provision sign informed consent Established clinical diagnosis type 2 diabetes . Treatment stable dose metformin monotherapy ( 15001700 mg/day ) least 8 week prior visit 1 . HbA1c ≥7.0 % ≤10.0 % Type 1 diabetes , history diabetic ketoacidosis hyperosmolar nonketonic coma . Renal impairment define creatinine clearance &lt; 60 mL/min/1.73 m2 Individuals , opinion investigator , participation study may pose significant risk patient could render patient unable successfully complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Randomised</keyword>
	<keyword>Double-blind</keyword>
</DOC>